Advertisement


Simron Singh, MD, on Neuroendocrine Tumors of the GI Tract: Results from the RADIANT-4 Trial

2016 Gastrointestinal Cancers Symposium

Advertisement

Simron Singh, MD, of the Toronto Sunnybrook Cancer Centre, discusses an analysis of data from this phase III study on the efficacy and safety of everolimus in advanced, progressive, nonfunctional neuroendocrine tumors of the GI tract and unknown primary (Abstract 315).



Related Videos

Colorectal Cancer

Krzysztof Bujko, MD, on Rectal Cancer: Results of a Phase III Trial

Krzysztof Bujko, MD, of the Maria Skłodowska Curie Memorial Cancer Centre, discusses the results of a multicenter Polish study on neoadjuvant chemoradiation for fixed cT3 or cT4 re...

Gastroesophageal Cancer

Dung T. Le, MD, on Gastric or Gastroesophageal Junction Cancer: Results From the CheckMate-032 Trial

Dung T. Le, MD, from Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, discusses study findings on the safety and activity of nivolumab monotherapy in advanced an...

Gastroesophageal Cancer

Somnath Mukherjee, MD, on Esophageal Adenocarcinoma: Results of the NEOSCOPE Trial

Somnath Mukherjee, MD, of Oxford University, discusses this phase II study of induction chemotherapy followed by either oxaliplatin/capecitabine- or paclitaxel/carboplatin-based ch...

Pancreatic Cancer

James L. Abbruzzese, MD, on Pancreatic Cancer: Expert Perspective

James L. Abbruzzese, MD, of Duke University, discusses the international outlook on patterns of care and their impact on outcomes.

Gastroesophageal Cancer

Yoon-Koo Kang, MD, PhD, on Gastric/Gastroesophageal Junction Adenocarcinoma: Trial Results for T-DM1 vs a Taxane

Yoon-Koo Kang, MD, PhD, of the Asan Medical Center, discusses findings from this multicenter, phase II/III study of ado-trastuzumab emtansine vs a taxane in patients with previousl...

Advertisement

Advertisement



Advertisement